These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21098082)

  • 1. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
    Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K
    Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
    Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma.
    Hadi M; Chen CC; Whatley M; Pacak K; Carrasquillo JA
    J Nucl Med; 2007 Jul; 48(7):1077-83. PubMed ID: 17574980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for Increasing Uptake of Radiolabeled
    Pollard JH; Menda Y; Zamba KD; Madsen M; O'Dorisio MS; O'Dorisio T; Bushnell D
    Cancer Biother Radiopharm; 2021 Oct; 36(8):632-641. PubMed ID: 34252288
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
    Kaji P; Carrasquillo JA; Linehan WM; Chen CC; Eisenhofer G; Pinto PA; Lai EW; Pacak K
    Eur J Endocrinol; 2007 Apr; 156(4):483-7. PubMed ID: 17389464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
    van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
    J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
    Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
    Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
    Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
    J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma.
    Cecchin D; Lumachi F; Marzola MC; Opocher G; Scaroni C; Zucchetta P; Mantero F; Bui F
    Endocr Relat Cancer; 2006 Jun; 13(2):525-33. PubMed ID: 16728579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems.
    More SS; Itsara M; Yang X; Geier EG; Tadano MK; Seo Y; Vanbrocklin HF; Weiss WA; Mueller S; Haas-Kogan DA; Dubois SG; Matthay KK; Giacomini KM
    Clin Cancer Res; 2011 Apr; 17(8):2339-49. PubMed ID: 21421857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled (4-Fluoro-3-Iodobenzyl)Guanidine Improves Imaging and Targeted Radionuclide Therapy of Norepinephrine Transporter-Expressing Tumors.
    Yamaguchi A; Hanaoka H; Higuchi T; Tsushima Y
    J Nucl Med; 2018 May; 59(5):815-821. PubMed ID: 29217738
    [No Abstract]   [Full Text] [Related]  

  • 16. Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.
    Martiniova L; Cleary S; Lai EW; Kiesewetter DO; Seidel J; Dawson LF; Phillips JK; Thomasson D; Chen X; Eisenhofer G; Powers JF; Kvetnansky R; Pacak K
    Nucl Med Biol; 2012 Feb; 39(2):215-26. PubMed ID: 21958851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[
    Ohshima Y; Sasaki I; Watanabe S; Sakashita T; Higashi T; Ishioka NS
    Nucl Med Biol; 2022; 112-113():44-51. PubMed ID: 35802985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
    Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
    Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
    J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
    Sait S; Pandit-Taskar N; Modak S
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.